Park Place Capital Corp trimmed its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 15.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,348 shares of the company’s stock after selling 444 shares during the period. Park Place Capital Corp’s holdings in Eli Lilly and Company were worth $2,126,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in LLY. Lipe & Dalton bought a new stake in Eli Lilly and Company in the 4th quarter valued at about $26,000. Tidemark LLC bought a new stake in Eli Lilly and Company in the 4th quarter valued at about $29,000. Core Wealth Advisors Inc. increased its position in Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares in the last quarter. Frank Rimerman Advisors LLC bought a new stake in Eli Lilly and Company in the 4th quarter valued at about $37,000. Finally, St. Johns Investment Management Company LLC boosted its stake in Eli Lilly and Company by 123.3% during the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock valued at $39,000 after purchasing an additional 37 shares during the last quarter. 82.53% of the stock is owned by institutional investors.
Eli Lilly and Company Stock Performance
LLY stock traded down $27.98 during midday trading on Friday, reaching $804.46. 3,515,933 shares of the company’s stock traded hands, compared to its average volume of 3,316,491. The company has a 50-day moving average price of $870.80 and a two-hundred day moving average price of $790.05. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. Eli Lilly and Company has a 52 week low of $446.89 and a 52 week high of $966.10. The firm has a market capitalization of $764.57 billion, a PE ratio of 118.48, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41.
Eli Lilly and Company Announces Dividend
Insider Buying and Selling at Eli Lilly and Company
In related news, major shareholder Lilly Endowment Inc sold 92,563 shares of the company’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $809.21, for a total value of $74,902,905.23. Following the completion of the transaction, the insider now directly owns 98,556,247 shares in the company, valued at $79,752,700,634.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Eli Lilly and Company news, EVP Johna Norton sold 7,056 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the completion of the sale, the executive vice president now directly owns 25,428 shares in the company, valued at $20,835,194.64. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 92,563 shares of the company’s stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the sale, the insider now owns 98,556,247 shares of the company’s stock, valued at $79,752,700,634.87. The disclosure for this sale can be found here. Insiders have sold 1,214,704 shares of company stock valued at $1,066,841,316 in the last 90 days. 0.13% of the stock is currently owned by company insiders.
Analyst Ratings Changes
A number of equities analysts have issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research note on Wednesday, July 24th. Berenberg Bank lifted their price target on Eli Lilly and Company from $850.00 to $1,000.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. The Goldman Sachs Group lifted their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. BMO Capital Markets reiterated an “outperform” rating and set a $1,001.00 price target on shares of Eli Lilly and Company in a research note on Wednesday, July 3rd. Finally, Barclays lifted their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $858.72.
View Our Latest Research Report on Eli Lilly and Company
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Further Reading
- Five stocks we like better than Eli Lilly and Company
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- What is a Dividend King?Â
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.